. 2022 Jun 13;2(1):vbac047. doi: 10.1093/bioadv/vbac047

Table 2.

TWAS features associated with PFS via treatment interaction in metastatic colorectal cancer patients from the MAVERICC clinical trial

					FDR for LRTs of ω
Symbol	$δ (95 % C I)$	$P_{δ}$	$ω (95 % C I)$	$P_{ω}$	q_BH	q_MV (95% CI)	( $q_{M V_{a}}$ 95% CI)
WDSUB1	0.01 (−0.16, 0.17)	0.95	−0.78 (−1.12, −0.44)	4.7e−6	0.026	0.025 (0.005, 0.13)	(0.004, 0.14)
CAVIN3	0.14 (−0.03, 0.31)	0.12	−0.78 (−1.12, −0.43)	1.0e−5	0.028	0.025 (0.005, 0.13)	(0.004, 0.14)
DYNC2H1	1.76 (−0.81, 4.33)	0.15	12.1 (4.7, 19.4)	6.2e−5	0.11	0.13 (0.04, 0.42)	(0.04, 0.46)
CCDC47	−0.08 (−0.25, 0.09)	0.36	0.65 (0.31, 0.99)	1.5e−4	0.21	0.24 (0.09, 0.66)	(0.08, 0.70)

$δ (95 % CI), ω (95 % CI)$ correspond to Model 3; P-values reported are for LRTs. Q-values correspond to FDR estimates for likelihood ratio tests of ω. q_BH denotes BH FDR, q_MV denotes MV FDR and $q_{M V_{a}}$ denotes BY adjusted CIs using 100 replicate permutations.